

**CDK10 Antibody (N-term)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP7516A****Specification**

---

**CDK10 Antibody (N-term) - Product Information**

Application	WB, IHC-P,E
Primary Accession	<a href="#">Q15131</a>
Other Accession	<a href="#">Q3UMM4</a>
Reactivity	Human
Predicted	Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Antigen Region	1-32

**CDK10 Antibody (N-term) - Additional Information****Gene ID** 8558**Other Names**

Cyclin-dependent kinase 10, Cell division protein kinase 10, Serine/threonine-protein kinase PISSLRE, CDK10

**Target/Specificity**

This CDK10 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-32 amino acids from the N-terminal region of human CDK10.

**Dilution**WB~~1:1000  
IHC-P~~1:50~100**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

CDK10 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

**CDK10 Antibody (N-term) - Protein Information****Name** CDK10

**Function** Cyclin-dependent kinase that phosphorylates the transcription factor ETS2 (in vitro) and positively controls its proteasomal degradation (in cells) (PubMed:[24218572](#)). Involved in the regulation of actin cytoskeleton organization through the phosphorylation of actin dynamics regulators such as PKN2. Is a negative regulator of ciliogenesis through phosphorylation of PKN2 and promotion of RhoA signaling (PubMed:[27104747](#)).

**Cellular Location**


Cytoplasm, cytoskeleton, cilium basal body

**CDK10 Antibody (N-term) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**CDK10 Antibody (N-term) - Images**



Western blot analysis of CDK10 antibody (N-term) (Cat. #AP7516a) pre-incubated with (Lane1) and without (Lane 2) blocking peptide (Cat. #BP7516a) in A375 cell line lysate. CDK10 (arrow) was detected using the purified Pab.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

#### **CDK10 Antibody (N-term) - Background**

CDK10 belongs to the CDK subfamily of the Ser/Thr protein kinase family. The CDK subfamily members are highly similar to the gene products of *S. cerevisiae* cdc28, and *S. pombe* cdc2, and are known to be essential for cell cycle progression. This kinase has been shown to play a role in cellular proliferation. Its function is limited to cell cycle G2-M phase.

#### **CDK10 Antibody (N-term) - References**

Crawford, J., et al., Genomics 56(1):90-97 (1999).  
Brambilla, R., et al., Oncogene 9(10):3037-3041 (1994).  
Grana, X., et al., Oncogene 9(7):2097-2103 (1994).  
Morgan, D. O. Annu. Rev. Cell Dev. Biol. 13, 261 (1997)  
Sherr, C. Science 274:1672 (1996)  
Kamb A. TIG 11:136 (1995)  
Zhang, H. et al, Cell 82, 915 (1995)  
Parge, HE. et al., Science 262, 387 (1993)  
Hershko, A. et al., Ann. Rev. Biochem. 61, 761 (1992)  
Peters, JM. Curr. Biol. 10, 759 (1998)  
Skowyra, D. et al., Cell 91, 209 (1997)  
Ganoth D. et al., Nature Cell Biol. 3, 321-324 (2001)

#### **CDK10 Antibody (N-term) - Citations**

- [Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.](#)
- [Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.](#)
- [Identification of nuclear structural protein alterations associated with seminomas.](#)
- [Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.](#)